Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins: the case for higher, individualized starting doses.

Peter H Jones1

  • 1Lipid Metabolism and Atherosclerosis Clinic, Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX, USA. jones@bcm.tmc.edu

Cleveland Clinic Journal of Medicine
|October 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2022
Same author

Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).

Journal of clinical lipidology·2021
Same author

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies.

Cardiology and therapy·2020
Same author

Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?"

Journal of clinical lipidology·2020
Same author

"Zero": The New Superhero or Superhero in Training?

Journal of the American College of Cardiology·2019
Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2019

Higher statin doses, tailored to individual lipid levels and cardiovascular risk, can help hypercholesterolemia patients reach their low-density lipoprotein cholesterol (LDL-C) goals. This approach may reduce cardiovascular events and mortality.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Hypercholesterolemia is a major risk factor for cardiovascular disease.
  • Current statin dosing strategies may not be optimal for all patients.
  • Achieving low-density lipoprotein cholesterol (LDL-C) targets is crucial for cardiovascular risk reduction.

Purpose of the Study:

  • To evaluate the impact of higher, tailored statin doses on LDL-C goal attainment in hypercholesterolemia patients.
  • To assess the potential reduction in cardiovascular events and mortality with optimized statin therapy.

Main Methods:

  • Retrospective analysis of patient data.
  • Stratification of patients based on baseline lipid levels and cardiovascular risk scores.
  • Comparison of LDL-C goal achievement rates between standard and higher, tailored statin dose groups.

Related Experiment Videos

Main Results:

  • Patients initiated on higher, tailored statin doses demonstrated significantly higher rates of LDL-C goal attainment.
  • A trend towards reduced cardiovascular events and mortality was observed in the higher-dose group, though further studies are needed.
  • Individualized dosing strategies are effective in managing hypercholesterolemia.

Conclusions:

  • Optimizing statin therapy with higher, individualized doses can improve LDL-C control in hypercholesterolemia.
  • Tailored statin regimens hold promise for reducing the burden of cardiovascular disease.
  • Personalized medicine approaches are essential for effective lipid management.